Amicus Therapeutics Inc (NASDAQ: FOLD) Surprises Bears With Upbeat Outlook.

In the last trading session, 3.99 million shares of the Amicus Therapeutics Inc (NASDAQ:FOLD) were traded, and its beta was 0.77. Most recently the company’s share price was $10.71, and it changed around -$0.11 or -1.02% from the last close, which brings the market valuation of the company to $3.16B. FOLD currently trades at a discount to its 52-week high of $14.57, offering almost -36.04% off that amount. The share price’s 52-week low was $9.70, which indicates that the current value has risen by an impressive 9.43% since then. We note from Amicus Therapeutics Inc’s average daily trading volume that its 3-month average coming to 3.03 million.

Amicus Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.55. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended FOLD as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Amicus Therapeutics Inc is expected to report earnings per share of -$0.07 for the current quarter.

Amicus Therapeutics Inc (NASDAQ:FOLD) trade information

Instantly FOLD has showed a red trend with a performance of -1.02% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -24.52% year-to-date, but still up 1.42% over the last five days. On the other hand, Amicus Therapeutics Inc (NASDAQ:FOLD) is -7.11% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $17, which translates to bulls needing to increase their stock price by 37.0% from its current value. Analyst projections state that FOLD is forecast to be at a low of $14 and a high of $20.

Amicus Therapeutics Inc (FOLD) estimates and forecasts

Amicus Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -1.74 percent over the past six months and at a 101.96% annual growth rate that is well above the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 61.10% in revenue this quarter, and will report an increase of 86.70% in the next quarter. The year-over-year growth rate is expected to be 32.50%, up from the previous year.

Consensus estimates provided by 10 financial analysts predict the company will bring in an average of $111.19 million in revenue for the current quarter. 10 analysts expect Amicus Therapeutics Inc to make $124.94 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $83.08 million and $94.5 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 33.80%. Forecasts for the next quarter put sales growth at 32.20%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.84%.